Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors

Thorvardur R Halfdanarson, Joseph Rubin, Michael B Farnell1, Clive S Grant1 and Gloria M Petersen2

Division of Oncology, Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
1Department of Surgery, Rochester, Minnesota, USA
2Department of Health Sciences Research, Rochester, Minnesota, USA

(Correspondence should be addressed to T R Halfdanarson who is now at Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa 52242, USA; Email: thorvardur-halfdanarson@uiowa.edu)

Abstract

Pancreatic endocrine tumors (PETs) are uncommon tumors with an annual incidence < 1 per 100,000 person-years in the general population. The PETs that produce hormones resulting in symptoms are designated as functional. The majority of PETs are non-functional. Of the functional tumors, insulinomas are the most common, followed by gastrinomas. The clinical course of patients with PETs is variable and depends on the extent of the disease and the treatment rendered. Patients with completely resected tumors generally have a good prognosis, and aggressive surgical therapy in patients with advanced disease may also prolong survival. The epidemiology, prognosis, and established and novel prognostic markers of PETs are reviewed.

Endocrine-Related Cancer (2008) 15 409–427

Introduction

Pancreatic endocrine tumors (PETs) are uncommon neoplasms with an incidence of <1 per 100,000 person-years in population studies (Moldow & Connelly 1968, Buchanan et al. 1986, Eriksson et al. 1989, Watson et al. 1989, Carriaga & Henson 1995, Lam & Lo 1997, Halfdanarson et al. 2007). The incidence is higher in autopsy studies, ranging from 0.8 to 10% suggesting that these tumors frequently go unnoticed (Grimalius et al. 1975, Kimura et al. 1991). PETs comprise <3% of all pancreatic neoplasms (Cubilla & Hajdu 1975, Carriaga & Henson 1995, Fesinmeyer et al. 2005, Öberg & Eriksson 2005). Pancreatic endocrine tumors are generally more indolent than adenocarcinoma of the pancreas and have a better prognosis (Carriaga & Henson 1995, Fesinmeyer et al. 2005). The origin of these tumors is not fully known, but they may arise from pluripotent cells within the exocrine pancreas (Vortmeyer et al. 2004). PETs are frequently divided into two groups based on their functional status, but unfortunately there is no uniformly accepted definition of a functional PET. Patients with ‘functional’ PETs commonly manifest symptoms resulting from hormone production of the tumor, although these tumors may also produce hormones without the patient having any symptoms secondary to the overproduced hormones. For the purpose of this review, we consider patients without symptoms of hormone production to have non-functional tumors even though elevated levels of hormones are detected in the blood, but we acknowledge the limitations of that definition. Multiple studies have addressed the epidemiology and prognosis of PETs but there are few large population studies available. A substantial proportion of the literature regarding these tumors stems from case reports and case series, often involving highly selected groups of patients, limiting the generalizability of the results. The purpose of this article is to review the epidemiology and prognosis of PETs and the commonly used prognostic predictors. We briefly discuss the role of novel prognostic markers.
Pathology and classification of PETs

Pancreatic endocrine tumors are frequently graded and classified according to the WHO classification of endocrine tumors (Table 1; Solcia et al. 2000, Heitz et al. 2004, Klöppel et al. 2004). The diagnosis of PETs rests upon confirming the neuroendocrine nature of the malignant cells. These tumors can have heterogeneous microscopic findings, and immunohistochemical staining with markers, such as chromogranin A, synaptophysin, and neuron-specific enolase, can usually confirm the neuroendocrine origin. It can be difficult to accurately assess the degree of malignancy of pancreatic endocrine tumors but the current WHO classification provides guidance in that respect. Other features of the tumors, including local invasion and metastases to lymph nodes and distant organs, have also been helpful in defining their malignant nature. The European Neuroendocrine Tumor Society has recently published guidelines on the management of PETs (Falconi et al. 2006, de Herder et al. 2006, O’Toole et al. 2006).

Epidemiology of PETs

Our knowledge of the epidemiology and risk factors for PETs is limited. While multiple studies have evaluated prognosis after diagnosis and therapy, few studies have focused on the epidemiology of PETs in defined populations. Not all studies separated PETs from other gastroenteropancreatic (GEP) neuroendocrine tumors, and thus provided limited information on tumors located in the pancreas. Other studies did not separate tumors with more indolent clinical behavior, such as insulinomas, from tumors showing more malignant behavior. Studies from large referral centers are common but may not represent the general population of patients with PETs. Furthermore, definitions of PETs have varied over the years, and until recently there was no consensus among pathologists regarding the diagnostic criteria or the criteria for malignant behavior.

The diverse nature of pancreatic tumors has been known for more than a century. It is of historical interest to review earlier reports on pancreatic tumors other than adenocarcinoma (Table 2). These studies have to be interpreted with caution as PETs were not well-defined entities at the time they were conducted, and there likely are substantial inaccuracies regarding the diagnoses. An autopsy study from the early twentieth century by Nicholls reports a case of pancreatic adenoma arising in the islet of Langerhans among 1514 patients (Nicholls 1902). Korpássy (1939) found four cases (0.8%) of macroscopic islet cell adenomas in 500 autopsies in 1938. Twenty-four cases (0.3%) of ‘benign islet cell neoplasms’ were observed in a series of 9158 consecutive autopsies reported by Frantz (1959). Warren et al. reported 24 islet cell tumors among 2708 autopsies of patients without diabetes and 18 tumors in 1858 diabetic patients, corresponding to a prevalence of 0.9% (Warren et al. 1966). Similar prevalence of 1.4% was reported by Becker where 62 ‘islet cell adenomas’ were found in 4280 autopsies (Becker 1971).

More recent studies have used more accurate diagnostic criteria for PETs providing better information on the prevalence of PETs in patients undergoing autopsy (Table 2). Eleven ‘endocrine adenomas’ were found among 1366 Swedish autopsy cases (0.8%; Grimelius et al. 1975). No patients carried the diagnosis of pancreatic tumor in life or had evidence of hormone overproduction. Twenty PETs were found among 800 consecutive patients (2.5%) undergoing autopsy in a Japanese geriatric hospital (Kimura et al. 1991). None of these patients had symptoms of excessive hormone secretion prior to their death but one patient had a prior history of resected gastrinoma. A randomly selected subset of 60 patients had 5 mm thick sections of the pancreas examined thoroughly and 6 (10%) were found to have an occult PET (Kimura et al. 1991). This study suggests that PETs may be much more common than previously thought the patients are frequently asymptomatic. Another study described 53 Chinese patients with PETs and estimated the annual incidence of symptomatic PETs to be 0.2/100 000. Furthermore, 11 472 autopsies were reviewed yielding 13 PETs (0.11%) where only 4 patients were symptomatic antemortem. The autopsy prevalence of asymptomatic PETs was thus 0.08% and

Table 1 WHO classification of pancreatic endocrine tumors (Heitz et al. 2004)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Benign behavior</td>
<td>Confined to the pancreas, &lt; 2 cm in diameter, ≤ 2 mitoses per 10 HPF, ≤ 2% Ki-67-positive cells, no angioinvasion, or perineural invasion</td>
</tr>
<tr>
<td>2. Uncertain behavior</td>
<td>Confined to the pancreas and one or more of the following features: ≥ 2 cm in diameter, &gt; 2 mitoses per 10 HPF, &gt; 2% Ki-67-positive cells, angioinvasion, perineural invasion</td>
</tr>
<tr>
<td>3. High-grade malignant</td>
<td>≥ 20 mitoses per HPF</td>
</tr>
</tbody>
</table>

HPF, high-power field.
the annual incidence of symptomatic PETs 0.2/100,000 (Lam & Lo 1997).

Several studies on the incidence of PETs in defined populations have been performed (Table 3; Moldow & Connelly 1968, Buchanan et al. 1986, Eriksson et al. 1989, Watson et al. 1989, Carriaga & Henson 1995, Lam & Lo 1997, Lepage et al. 2004, Halfdanarson et al. 2007). Moldow & Connelly reported on all patients diagnosed with pancreatic tumors in Connecticut during 1957–1963 (Moldow & Connelly 1968). Out of the 856 pancreatic tumors, islet cell tumors accounted for 5%. In this study, no effort was made to distinguish between islet cell tumors and other rare pancreatic tumors. These tumor types in addition to PETs comprised 5% of all pancreatic tumors and the incidence was <1/100,000 (Moldow & Connelly 1968). A Swedish study reported an annual incidence of 0.4/100,000 (Eriksson et al. 1989) and a study from Northern Ireland found an annual incidence of 0.18/100,000 (Buchanan et al. 1986). The latter study was later updated reporting the incidence to be 0.23/100,000 (Watson et al. 1989).

A recent French study using a population-based cancer registry found the overall annual crude incidence of malignant digestive endocrine tumors to be 1.15/100,000 for men and 0.91/100,000 for women. Pancreatic tumors accounted for 20.5% of all tumors in this cohort. The age-standardized incidence rates of PETs were 0.19/100,000 and 0.12/100,000 for men and women respectively, with a male-to-female ratio of 1.6 (Lepage et al. 2004).

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Number of PET cases in the population</th>
<th>Annual incidence (all types)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moldow 1968</td>
<td>NR</td>
<td>&lt;1/100,000&lt;sup&gt;a&lt;/sup&gt;</td>
<td>All cases in Connecticut, USA over a given period; PETs grouped with other rare tumors of the pancreas</td>
</tr>
<tr>
<td>Eriksson 1989</td>
<td>84</td>
<td>0.4/100,000</td>
<td>Well-defined region in Sweden; single referral hospital</td>
</tr>
<tr>
<td>Watson 1989</td>
<td>94</td>
<td>0.23/100,000</td>
<td>Well-defined Northern Irish population; same series as Buchanan et al. (1986)</td>
</tr>
<tr>
<td>Carriaga 1995</td>
<td>402</td>
<td>&lt;0.6/100,000&lt;sup&gt;a&lt;/sup&gt;</td>
<td>SEER data 1973–1987; exact incidence of PETs not provided</td>
</tr>
<tr>
<td>Lam 1997</td>
<td>53</td>
<td>0.2/100,000</td>
<td>Referral to a single hospital in Hong Kong</td>
</tr>
<tr>
<td>Lepage 2004</td>
<td>47</td>
<td>0.12/100,000</td>
<td>Well-defined geographic region in France</td>
</tr>
<tr>
<td>Halfdanarson 2007</td>
<td>1488</td>
<td>0.19/100,000&lt;sup&gt;c&lt;/sup&gt;</td>
<td>SEER data 1973–2000; all (neuro)endocrine tumors of the pancreas</td>
</tr>
</tbody>
</table>

<sup>a</sup>Sixty patients of the 800 were randomly selected for a thorough pathological examination with 5 mm sections of the pancreas.

NR, not reported; SEER, surveillance, epidemiology, and end results.

<sup>c</sup>Accurate figure not provided for pancreatic endocrine tumors.
The incidence rates were low in persons under 40 years of age but increased steadily with age, reaching a peak at the age of 75 for men and 65 for women. A study using the Surveillance, Epidemiology, and End Results (SEER) registry data from 1973 to 1987 found the annual incidence of <0.6/100,000 for all age groups (Carriaga & Henson 1995). We have recently presented our data on all PETs in the SEER registry from 1973 to 2000. The overall annual incidence of PETs was 0.2/100,000 with the highest incidence (0.7–0.8/100,000) in the sixth and seventh decades with a slight male predominance (Halfdanarson et al. 2007). The incidence has increased over time, possibly related to increased awareness of these tumors among clinicians.

The frequency of the various subtypes of functional PETs has been described in several studies (Tables 4 and 5; Jacobsen et al. 1986, Cullen & Ong 1987, Eriksson et al. 1989, 1990, Watson et al. 1989, Service et al. 1991, Stamm et al. 1991). Insulinoma is the most frequently encountered functional PET and is usually a benign tumor and almost always located in the pancreas (Soga & Yakuwa 1994, Öberg & Eriksson 2005). The incidence of insulinoma in a well-defined population in Olmsted County (Kavlie & White 1972, Cullen & Ong 1987, Eriksson et al. 1989, Watson et al. 1989). The annual incidence of malignant insulinoma in the SEER registry is 0.1/million (Halfdanarson et al. 2008). Gastrinoma is the second most commonly encountered functional PET but gastrinomas are also frequently found outside the pancreas (Soga & Yakuwa 1998a, Norton et al. 1999, Roy et al. 2000, Öberg & Eriksson 2005). Pancreatic gastrinomas may be more aggressive and frequently associated with liver metastases (Weber et al. 1995). Up to 30% of gastrinomas are associated with multiple endocrine neoplasia type 1 (MEN-1; Soga & Yakuwa 1998a, Roy et al. 2000). Gastrinoma is the most common functional PET seen in patients with MEN-1 and the prognosis may be worse than that in sporadic gastrinoma (Norton et al. 1999, Gibril et al. 2001, Norton 2005). Investigators in Denmark estimated the incidence of gastrinoma to be 0.5 per million per year (Jacobsen et al. 1986). A higher incidence of 2–4 per million has been found in Switzerland (Stamm et al. 1991). Other studies have reported an annual incidence of 0.5–1.2 cases per million (Eriksson et al. 1989, Watson et al. 1989). Our recent study using the SEER registry suggested an annual incidence of 0.1/million, but this may be a substantial underestimate given the way that SEER registers these tumors (Halfdanarson et al. 2008).

Epidemiological data on functioning PETs other than insulinoma and gastrinoma is sparse. Pancreatic endocrine tumors secreting vasoactive intestinal peptide (VIPoma) comprise <10% of all PETs and appear to be slightly more common in females according to some but not all reports (Klöppel & Heitz 1988, Solcia et al. 1997, Smith et al. 1998, Soga & Yakuwa 1998c, Peng et al. 2004). VIPomas are found in extrapancreatic locations in up to 25% of cases (Soga & Yakuwa 1998c). Two studies have reported the annual incidence of VIPoma to be 0.1–0.6 per million but the incidence of pancreatic VIPomas is not well known (Eriksson et al. 1989, Watson et al. 1989). Glucagon-secreting tumors (glucagonomas) represent <10% of PETs and are almost exclusively found within the pancreas (Klöppel & Heitz 1988, Solcia et al. 1997). Glucagonomas are very rare and their annual incidence has been estimated to be around or <0.1 per million (Eriksson et al. 1989, Watson et al. 1989). Glucagonomas may be slightly more common among females and

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Country</th>
<th>Annual incidence of all PETs</th>
<th>Insulinoma</th>
<th>Gastrinoma</th>
<th>VIPoma</th>
<th>Glucagonoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eriksson 1989</td>
<td>Sweden</td>
<td>4</td>
<td>1.1</td>
<td>1.2</td>
<td>0.64</td>
<td>0.04</td>
</tr>
<tr>
<td>Watson 1989</td>
<td>Northern Ireland</td>
<td>2.3</td>
<td>1.2</td>
<td>0.5</td>
<td>0.12</td>
<td>0.12</td>
</tr>
<tr>
<td>Service 1991</td>
<td>USA</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cullen 1987</td>
<td>New Zealand</td>
<td>0.67</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Jacobsen 1986</td>
<td>Denmark</td>
<td>–</td>
<td>–</td>
<td>0.5</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Stamm 1991</td>
<td>Switzerland</td>
<td>–</td>
<td>2–4</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
Table 5 Subtypes of pancreatic endocrine tumors

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>Annual incidence (cases per million)</th>
<th>Percentage of all PETs (%)</th>
<th>Age (years)</th>
<th>Percent malignant</th>
<th>Percent located in the pancreas (%)</th>
<th>Percent associated with MEN-1 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulinoma</td>
<td>0.7–4.0</td>
<td>30–45</td>
<td>30–60</td>
<td>5–10</td>
<td>&gt;95</td>
<td>4–8</td>
</tr>
<tr>
<td>Gastrinoma</td>
<td>0.5–4.0</td>
<td>16–30</td>
<td>20–70</td>
<td>40–90</td>
<td>25–70</td>
<td>12–22</td>
</tr>
<tr>
<td>VIPoma</td>
<td>0.1–0.6</td>
<td>&lt;10</td>
<td>20–80</td>
<td>&gt;50</td>
<td>75–90</td>
<td>6–11</td>
</tr>
<tr>
<td>Glucagonoma</td>
<td>≤0.1</td>
<td>&lt;10</td>
<td>40–60</td>
<td>&gt;50</td>
<td>&gt;95</td>
<td>5–13</td>
</tr>
<tr>
<td>Somatostatinoma</td>
<td>&lt;0.1</td>
<td>&lt;5</td>
<td>30–80</td>
<td>&gt;60</td>
<td>40–70</td>
<td>2–7</td>
</tr>
<tr>
<td>Other hormones b</td>
<td>Rare</td>
<td>&lt;1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Unknown</td>
</tr>
<tr>
<td>Non-functioning c</td>
<td>≤1</td>
<td>25–100</td>
<td>50–60</td>
<td>&gt;50</td>
<td>100</td>
<td>0–21</td>
</tr>
<tr>
<td>(clinically silent)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


bMalignant behavior based on the presence of invasion and metastases.

Data on these tumors are insufficient for further analysis.

Includes tumors that produce pancreatic polypeptide (PP).

The higher percentage comes from autopsy series.

patients are usually in their fifth decade at the time of diagnosis (Wermers et al. 1996, Soga & Yakuwa 1998b). PETs secreting somatostatin (somatostatinoma) are rare and account for <5% of all PETs and the true incidence of these tumors is unknown. Somatostatinomas typically present in the fifth and sixth decades of life with a slight female preponderance. Up to 50% of somatostatinomas arise outside the pancreas (Harris et al. 1987, Konomi et al. 1990, Soga & Yakuwa 1999). Pancreatic tumors secreting other hormones such as cholecystokinin, gastric inhibitory peptide, gastrin-releasing peptide (GRP), adrenocorticotrophin (ACTH), growth hormone-releasing hormone, PTHrP, and ghrelin are extremely rare and their incidence is unknown.

Non-functioning tumors comprise a substantial proportion of all PETs and have been reported to comprise 25–100% of all PETs. The annual incidence of symptomatic non-functional PETs has been estimated to be 0.07–0.1/100 000 (Eriksson et al. 1989, Watson et al. 1989). Autopsy studies have shown much higher incidence than that reported in clinical series (Kimura et al. 1991).

PETs associated with hereditary syndromes

Pancreatic endocrine tumors are commonly observed in MEN-1 and less frequently in von Hippel–Lindau disease (VHL). Cases of PET in association with the tuberous sclerosis complex and type 1 neurofibromatosis have also been reported but are rare (Tan et al. 1996, Verhof et al. 1999, Fujisawa et al. 2002, Fracalanci et al. 2003).

The MEN-1 syndrome is an autosomal dominant inherited disorder characterized by multiple endocrine and non-endocrine tumors (Brandi et al. 2001, Doherty 2005, Lakhani et al. 2007). The endocrine tumors most frequently described in patients with MEN-1 include parathyroid adenomas, pituitary adenomas, and PETs. Multiple other tumors of varying penetrance have been reported in association with MEN and include tumors of the adrenal glands, carcinoid tumors, angiofibroma, collagenoma, and lipoma. The penetrance of PETs in MEN-1 patients ranges from 30 to 75% and these tumors are frequently multifocal and metastatic at the time of diagnosis (Vasen et al. 1989, Skogseid et al. 1991, Le Bodic et al. 1996, Burgess et al. 1998a, b). Gastrinomas are the most commonly encountered PETs, followed by non-functioning tumors and insulinomas (Brandi et al. 2001, Gibril & Jensen 2004, Triponez et al. 2006). A recent study suggested that non-functioning tumors were more common than gastrinomas in MEN-1 patients (Triponez et al. 2006). PETs are a major cause of morbidity and mortality in patients with MEN-1, but discussion of screening and treatment of these patients is outside the scope of this review (Wilkinson et al. 1993, Doherty et al. 1998, Dean et al. 2000). VHL disease is an autosomal dominant tumor predisposition syndrome caused by a germ line mutation in the VHL gene (Lonser et al. 2003). The typical features of VHL disease include retinal and brain hemangioblastoma, renal cell carcinoma, renal cysts, phaeochromocytoma, and pancreatic tumors and cysts (Lonser et al. 2003). Pancreatic
endocrine tumors are found in 9.5–17% of patients with VHL disease (Binkovitz et al. 1990, Libutti et al. 1998, Hammel et al. 2000, Blansfield et al. 2007). The PETs associated with VHL disease are virtually always non-functional (Blansfield et al. 2007).

**Prognosis following resection**

**Functional and non-functional tumors**


Table 6 lists the studies of patients with both functional and non-functional tumors, who have undergone resection. The extent of the disease and the completeness of resection were major predictors of survival in most of these series (Legaspi & Brennan 1988, Thompson et al. 1988, Lo et al. 1996, Phan et al. 1997, Madeira et al. 1998, Chu et al. 2002, Hochwald et al. 2002, Lepage et al. 2004, Pape et al. 2004, Panzuto et al. 2005, Tomassetti et al. 2005, House et al. 2006). Several studies have suggested that the functional status of the tumors may affect prognosis. Functional tumors have been reported to have a better prognosis than non-functional tumors (Thompson et al. 1988, Phan et al. 1998, Sarmiento et al. 2002). Other studies have either reported worse prognosis of functional tumors or no effect of functional status on prognosis (Cubilla & Hajdu 1975, White et al. 1994). We have recently reported our analysis of the SEER data on PETs where functional tumors had a better prognosis after adjusting for other predictors such as age and stage. We also found that prognosis has improved with time and the improvement does not seem to be explained by stage migration. It is possible that more aggressive surgical therapy or improved medical care has resulted in better prognosis (Halfdanarson et al. 2007).

Taken together, these studies of heterogeneous cohorts of patients with both functional and non-functional tumors have not consistently shown functional status to be a prognostic factor in terms of survival when the benign insulinomas have been excluded. The heterogeneity of the studies makes all comparisons difficult. Ninety percent of insulinomas are benign and have excellent prognosis after resection (Service et al. 1991). Patients with gastrinoma seem to have a better survival than those with other malignant and functional PETs, especially after surgery with curative intent (Norton et al. 1999). As expected, patients with more advanced and metastatic diseases as well as those with residual disease following resection had shorter survival.

**Non-functional tumors**


La Rosa et al. (1996) studied 61 patients with non-functional PETs. The tumors were considered malignant if there was a direct invasion into adjacent tissues or organs or if distant metastases were present.
Table 6 Selected studies of both functional and non-functional pancreatic endocrine tumors

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Number of patients</th>
<th>Number (%) of functioning tumors</th>
<th>Number (%) of insulinomas</th>
<th>Number of patients with metastases at diagnosis (%)</th>
<th>Survival</th>
<th>Factors adversely affecting overall survival or disease-free survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cubilla et al. 1975 (Cubilla &amp; Hajdu 1975)</td>
<td>30</td>
<td>12 (34)</td>
<td>4 (13)</td>
<td>LN: 19 (63)</td>
<td>5-OS: 57%</td>
<td>Functional tumor</td>
</tr>
<tr>
<td>Broughan et al. 1986 (Broughan et al. 1986)</td>
<td>84</td>
<td>63 (75)</td>
<td>41 (49)</td>
<td>Liver: 21 (70)</td>
<td></td>
<td>Liver and/or LN: 39 (46%)</td>
</tr>
<tr>
<td>Phan et al. 1998 (Phan et al. 1998)</td>
<td>125</td>
<td>64 of all tumors (52)</td>
<td>35 (28)</td>
<td>NR</td>
<td></td>
<td>5-OS: 63.1% (N), 68.4% (G), 96.9 (I)</td>
</tr>
<tr>
<td>Sarmiento et al. 2002 (Sarmiento et al. 2002)</td>
<td>29</td>
<td>9 (31)</td>
<td>3 (10)</td>
<td>LN: 16 (55) Liver: 1 (3)</td>
<td>3-OS: 62%</td>
<td>Non-functional tumors, positive margins, malignant tumorsa</td>
</tr>
<tr>
<td>White et al. 1994 (White et al. 1994)</td>
<td>28</td>
<td>19 (68)</td>
<td>3 (11)</td>
<td>44% (N) 53% (NF)</td>
<td>DFS at 2 years: 67% (N) and 40% (F)</td>
<td>Non-functional, positive lymph nodesa</td>
</tr>
<tr>
<td>Jarufe et al. 2005 (Jarufe et al. 2005)</td>
<td>44</td>
<td>24 (55)</td>
<td>16 (36)</td>
<td>22 (50)</td>
<td>5-OS: 74.4%</td>
<td>Metastases (multivariate analysis)</td>
</tr>
<tr>
<td>Thompson et al. 1988 (Thompson et al. 1988)</td>
<td>58</td>
<td>31 (54)</td>
<td>8 (14)</td>
<td>LN: 25 (43) Liver: 19 (33)</td>
<td>5-OS: 42%</td>
<td>Liver metastases, non-functional tumor (versus gastrinoma)a</td>
</tr>
<tr>
<td>Legaspi et al. 1988 (Legaspi &amp; Brennan 1988)</td>
<td>33</td>
<td>11 (33)</td>
<td>0</td>
<td>Distant metastases: 16 (48)</td>
<td>3-year survival 76%</td>
<td>Incomplete resection or residual tumora</td>
</tr>
<tr>
<td>Lepage et al. 2004 (Lepage et al. 2004)</td>
<td>47</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>5-OS: 42%</td>
<td>Metastatic disease and advanced age (multivariate analysis)</td>
</tr>
<tr>
<td>Venkatesh et al. 1990 (Venkatesh et al. 1990)</td>
<td>98</td>
<td>55 (56)</td>
<td>7 (7)</td>
<td>47 (48)</td>
<td>Mean survival 42.7±49 months</td>
<td>Non-functional tumorsa metastatic disease and advanced age (multivariate analysis)</td>
</tr>
<tr>
<td>Tomassetti et al. 2005 (Tomassetti et al. 2005)</td>
<td>83</td>
<td>31 (37)</td>
<td>7 (8)</td>
<td>LN: 47 (60) Liver: 27 (33)</td>
<td>MS: 90 months 5-OS: 55.3%</td>
<td>Liver and lymph node metastases at diagnosis and incomplete resection, MEN-1a</td>
</tr>
<tr>
<td>Chu et al. 2002 (Chu et al. 2002)</td>
<td>50</td>
<td>21 (42)</td>
<td>6 (12)</td>
<td>Liver: 29 (58) Synchro-nous liver metastases</td>
<td>3-year survival: curative resection: 80%, non-curative resection 62%</td>
<td>Liver metastases, non-curative resectiona</td>
</tr>
<tr>
<td>Lo et al. 1996 (Lo et al. 1996)</td>
<td>64</td>
<td>30 (47)</td>
<td>4 (6)</td>
<td>LN: 38 (59) Liver: 39 (61)</td>
<td>5-OS: 55%</td>
<td>Liver metastases, poor differentiation and incomplete resection (multivariate analysis)</td>
</tr>
<tr>
<td>Madeira et al. 1998 (Madeira et al. 1998)</td>
<td>82b</td>
<td>38 (46)</td>
<td>3 (4)</td>
<td>LN: 52 (83) Liver: 49 (60) (among all 82 patients)</td>
<td>5-OS: No liver metastases 100% Liver metastases 40%</td>
<td>Liver metastases, non-curative resectiona</td>
</tr>
<tr>
<td>Pape et al. 2004 (Pape et al. 2004)</td>
<td>254</td>
<td>53 (32)</td>
<td>6 (8)</td>
<td>LN: 53 (73)</td>
<td>5-OS: 42.9%</td>
<td>Metastases at diagnosis and incomplete resectiona</td>
</tr>
<tr>
<td>Hochwald et al. 2002 (Hochwald et al. 2002)</td>
<td>136</td>
<td>47 (35)</td>
<td>21 (15)</td>
<td>NR</td>
<td>DFS after curative resection: 110 months (N) and 152 months (F)</td>
<td>High mitotic rate (DSS), presence of tumor necrosis, LN or liver metastases (DFS) (multivariate analysis)</td>
</tr>
<tr>
<td>House et al. 2006 (House et al. 2006)</td>
<td>31</td>
<td>8 (26)</td>
<td>1 (3)</td>
<td>100</td>
<td>MS: 77 months 5-OS: 78%</td>
<td>Incomplete resection</td>
</tr>
</tbody>
</table>
Multiple tumor characteristics predicted malignant behavior in a univariate analysis, including tumor diameter, vascular and perineural invasion, the presence of mitoses, nuclear atypia, and high proliferative index (Ki-67) as evaluated by Ki-67 immunohistochemical staining. The tumors were classified according to the histological features and Ki-67 proliferative index (Ki-67 PI) into four groups. Malignant tumors were also classified as poorly differentiated based on the appearance of the tumor cells and the presence of mitoses and areas of necrosis.

All other PETs were classified into limited risk tumors (LRT) and increased risk tumors (IRT) based on the presence of either high Ki-67 PI (>2%) or vascular and/or perineural invasion. These subtypes were found to predict survival in a univariate analysis. LRT had better prognosis than IRT, which in turn had better prognosis than well-differentiated carcinomas. The poorly differentiated carcinomas had the worst prognosis. Even though capsular penetration, the presence of distant metastases, vascular microinvasion, and high Ki-67 PI all were found to adversely affect survival in a univariate analysis, the predictive value disappeared on a multivariate analysis (La Rosa et al. 1996).

Functional tumors


As expected, the survival of patients with benign insulinoma was long following therapy and did not differ from expected survival of this population. The 10-year survival of patients with benign insulinoma was 78%. The factors adversely affecting the survival of patients with MEN-1 in addition to the MEN-1 phenotype were advanced age and patients diagnosed early in the study period. Among patients with MEN-1, the survival of patients with MEN-1 who were diagnosed before the age of 16 was 100%. The survival of patients with MEN-1 who were diagnosed after the age of 16 was 85%.

Factors adversely affecting overall survival or disease-free survival

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Number of patients</th>
<th>Number (%) of functioning tumors</th>
<th>Number (%) insulinomas</th>
<th>Number of patients with metastases at diagnosis (%)</th>
<th>Survival</th>
<th>Resection of primary tumor only: 17 months</th>
<th>Malignant tumors (neuroendocrine carcinoma)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kazanjian et al. 2006 (Kazanjian et al. 2006)</td>
<td>70</td>
<td>20 (29)</td>
<td>16 (23)</td>
<td>LN: 21 (57%) Liver: 9 (24%)</td>
<td>5-OS: 89%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Hellman et al. 2000 (Hellman et al. 2000)</td>
<td>31</td>
<td>7 (23)</td>
<td>NR</td>
<td>LN: 10 (32) Liver: 10 (32)</td>
<td>5-OS: 75%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Corletto et al. 2001 (Corletto et al. 2001)</td>
<td>98 a (including 41 PETs)</td>
<td>18 (44)</td>
<td>5 (12)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Schurr et al. 2007 (Schurr et al. 2007)</td>
<td>62</td>
<td>18 (44)</td>
<td>5 (12)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>

DFS, disease-free survival; DSS, disease-specific survival; F, functional PET; G, gastrinoma; I, insulinoma; LN, lymph nodes; MS, median survival; 5-OS, 5-year overall survival; N, non-functional PET; NR, not reported; NS, not significant.

aUnivariate analysis (results of univariate analyses are not reported where results of multivariate analyses are provided).

bThe study included both pancreatic and extrapancreatic tumors.

The number of patients with metastatic lesions relates to the 37 patients with neuroendocrine carcinoma.

dOut of 11 functional tumors, 10 were gastrinomas.
<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Number of patients</th>
<th>Metastasis at diagnosis (%)</th>
<th>Survival</th>
<th>Factors adversely affecting survival</th>
</tr>
</thead>
</table>
Liver 11 (44) | 3- and 5-year OS: 60 and 44% | NR |
| Eckhauser et al. 1986 (Eckhauser et al. 1986) | 11 | 9 (82)  
Liver: 5 (45)  
LN: 7 (64) | Mean survival: 23 months (4–72 months) | No predictors identified |
| Evans et al. 1993 (Evans et al. 1993) | 73 | 37 (51) | 5-year OS: 50% | Metastatic disease and incomplete resection<sup>a</sup> |
LN: 5 (25) | Median survival: Curative resection: 42 months | No curative resection: 32 months |
| La Rosa et al. 1996 (La Rosa et al. 1996) | 61 | 34 (56)  
LN: 5 (25) | Mean survival (months): Increased risk: 50.7  
Well differentiated: 44.2  
Poorly differentiated: 3.7 | Capsular penetration, distant metastases, vascular microinvasion, and high Ki-67 proliferative index<sup>a</sup> |
| Matthews et al. 2000 (Matthews et al. 2000) | 28 | 6 (21) | 2-year survival: node negative 77.8%, node positive 71.4 and metastatic 36.4 | Liver metastases<sup>a</sup> |
| Bartsch et al. 2000 (Bartsch et al. 2000) | 17 | LN: 15 (83)  
Distant: 6 (33) | 5- and 10-year OS: 65.4% and 49.1%. 5-year OS 100% in the completely resected patients versus 14.3% in patients treated with palliative intent | Incomplete resection<sup>a</sup> |
| Solorzano et al. 2001 (Solorzano et al. 2001) | 163 | 101 (62) | 5-year OS: 43% (77% in patients with localized and resected disease, 16% in patients with metastatic disease and no resection) | Incomplete resection, no anti-cancer therapy and age > 65 years (multivariate analysis) |
| Gullo et al. 2003 (Gullo et al. 2003) | 184 | 69 (38) | 5-year OS: resected 76.9%, not resected 28.6% | Metastatic disease, incomplete resection, symptomatic at diagnosis and tumor > 3 cm<sup>a</sup> |
| Liang et al. 2004 (Liang et al. 2004) | 43 | 6 (14) | 5- and 10-year OS: 58 and 29% | Incomplete resection (multivariate analysis) |
| Kang et al. 2005 (Kang et al. 2005) | 19 | 7 (37) | 5-year OS: 32% (curative resection 90%) | Metastases, unresectable disease, macroscopic invasion<sup>a</sup> |
| Guo et al. 2004 (Guo et al. 2004) | 41 (all patients had resection) | 4 (10) | NR | NR |
| Furukawa et al. 1998 (Furukawa et al. 1998) | 16 | 4 (25)  
LN: 2 (13)  
Liver: 2 (13) | 5-year OS: 83% | Tumors recurred in three patients following enucleation |
| Yang et al. 2000 (Yang et al. 2000) | 16 | LN: 8 (50)  
Liver: 2 (13) | All patients alive after a mean follow-up time of 5.3 years (one with recurrent disease) | Both patients with liver metastasis died secondary to their malignancy |
| Madura et al. 1997 (Madura et al. 1997) | 14 | LN: 7 (50) | Median survival 31.2 months | LN metastases |

LN, lymph nodes; NR, not reported; OS, overall survival.  
<sup>a</sup>Univariate analysis.
225 patients with benign insulinoma, who underwent resection from 1982 to 2004 (Grant 2005). The outcome for this cohort of patients was excellent, with 98% of patients being cured with resection. The general good outcome of patients with insulinoma may thus skew the outcome results in a series where patients with insulinomas are grouped with patients having other functional or non-functional tumors.

Norton et al. 1999 reported their experience with 151 patients with gastrinoma undergoing surgery. Their cohort of patients included 36 (24%) patients with pancreatic gastrinoma, of which 19 had MEN-1. Gastrinoma was localized to the pancreas in 17 out of 123 (14%) patients with sporadic tumors. The 5- and 10-year disease-specific survival of all patients with sporadic gastrinoma was 100 and 95% respectively and 40% of the patients were free of disease at 5 years postoperatively. A previous study by the same investigators showed that survival was primarily determined by the presence of liver metastases (Weber et al. 1995). Gastrinomas associated with the Cushing syndrome seem to have a particularly poor prognosis (Maton et al. 1986, Ilias et al. 2005).

Other prognostic factors

Several investigators have attempted to evaluate previously established and novel prognostic factors in PETs. The WHO classification of PETs has been shown to be useful in predicting the clinical behavior of these tumors Heymann et al. (2000). Histological findings such as grade and the number of mitotic figures have been found to predict survival in a few studies. Hochwald et al. (2002) retrospectively evaluated 136 patients with low-grade or intermediate-grade PETs who had undergone tumor resection. After adjusting for other prognostic factors including the presence of distal metastases, tumor necrosis was found to be associated with shorter disease-free survival (DFS). Higher tumor mitotic rate (> 2 per 50 high-power fields (HPFs)) was associated with shorter disease-specific survival (DSS). There was no difference in DFS or DSS between functional and non-functional tumors. The authors proposed a simple system for grading these tumors based on the presence of necrosis and the number of mitoses where patients with a low-grade tumor (<2 mitoses per 50 HPFs and no necrosis) had a significantly longer DFS and DSS (Hochwald et al. 2002). Other authors have suggested a prognostic model for well-differentiated gastroenteropathic neuroendocrine tumors (GEP-NET) using abnormal liver chemistries and urinary excretion of 5-HIAA, but the model has not been validated in patients with tumors limited to the pancreas (Formica et al. 2006). Proliferation markers such as Ki-67 immunohistochemistry have been found to predict prognosis in patients with PETs (Lloyd 1998). However, the results have not uniformly supported the prognostic value of increased Ki-67 expression, especially after adjusting for other known prognostic variables such as stage (La Rosa et al. 1996, Pelosi et al. 1996, 1997, Clarke et al. 1997, Gentil Perret et al. 1998, Lloyd 1998, Jorda et al. 2003, Goto et al. 2004, Böhnmig et al. 2005, Panzuto et al. 2005, Couvelard et al. 2006). Recent studies have identified additional markers that may be of prognostic value. Positive staining for CD19 was shown to be a powerful prognostic factor predicting shorter survival, even after controlling for variables such as the number of mitoses, tumor necrosis, and Ki-67 expression (Deshpande et al. 2004). CK19 may not be predictive of survival in patients with non-functional PETs (La Rosa et al. 2007). Expression of CD10 has also been shown to predict worse survival, and a correlation was found between CD10 expression and the WHO classification where the more malignant tumors were more likely to express CD10 (Deschamps et al. 2006). There was also a correlation between positive CD10 staining and higher proliferative index, larger tumor size, and the presence of hepatic metastases. Loss of expression of CD99 has been suggested to predict worse outcome by some authors but not others (Goto et al. 2004, Ali et al. 2006) and expression of CD44 isoforms v6 and v9 may be indicative of more benign behavior and better prognosis in patients with PET (Imam et al. 2000).

With advances in genetic and molecular biology, multiple potential prognostic markers have been identified. These markers have not yet been validated in large cohorts of patients and have not found their way into routine clinical use. The molecular genetics of GEP tumors have been reviewed in detail elsewhere (Zikusoka et al. 2005). Certain chromosomal aberrations have been found more frequently in patients with metastatic PETs when compared with non-metastatic tumors. These aberrations involve multiple chromosomes, including 1,3,5,6,7,14,22 and the X chromosome (Speel et al. 1999, Barghorn et al. 2001a,b, Zhao et al. 2001, Guo et al. 2002a,b, Wild et al. 2002, Chen et al. 2003, 2004). Chromosomal instability as manifested by the number of aberrations per tumor has been shown to be an indicator for the development of
Table 8 Selected studies of functional pancreatic endocrine tumors

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Number of patients</th>
<th>Median age (years)</th>
<th>Type of tumor (hormone produced)</th>
<th>Malignant PET (%) number of patients with metastases</th>
<th>Survival</th>
<th>Factors adversely affecting survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service et al. 1991</td>
<td>244</td>
<td>47</td>
<td>Insulinoma</td>
<td>5.8</td>
<td>10-year OS: 78% for benign and 29% for malignant insulinoma</td>
<td>Malignant insulinoma, advanced age</td>
</tr>
<tr>
<td>Grant 2005 (Grant 2005)</td>
<td>225</td>
<td>NR</td>
<td>Insulinoma</td>
<td>0</td>
<td>98% cure rate</td>
<td>NR</td>
</tr>
<tr>
<td>Grama et al. 1992</td>
<td>85</td>
<td>NR</td>
<td>Insulinoma 56%</td>
<td>47</td>
<td>10 OS: insulinoma 50%, malignant PET 28%</td>
<td>Liver metastases, tumor &gt; 4 cm, complete resection</td>
</tr>
<tr>
<td>Norton et al. 1999</td>
<td>151 (36 with pancreatic gastrinoma)</td>
<td>48 (mean age)</td>
<td>Gastrinoma a</td>
<td>NR</td>
<td>5-year OS: 100% for sporadic gastrinoma, 42% free of disease at 5 years</td>
<td>MEN-1 (lower disease-free survival)</td>
</tr>
<tr>
<td>Danforth et al. 1984</td>
<td>17</td>
<td>NR</td>
<td>Insulinoma</td>
<td>17 (100) LN: 8 (47)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Hirshberg et al. 2005</td>
<td>10</td>
<td>NR</td>
<td>Insulinoma</td>
<td>100</td>
<td>Survival ranged from 4 months to 30 years</td>
<td>NR</td>
</tr>
<tr>
<td>Matthews et al. 2002</td>
<td>20</td>
<td>NR</td>
<td>Gastrinoma 8 (40)</td>
<td>Metastases 5 (20)</td>
<td>63% survival at a mean follow-up of 47 months</td>
<td>NR</td>
</tr>
<tr>
<td>Harrison et al. 1973</td>
<td>35</td>
<td>NR</td>
<td>Insulinoma</td>
<td>Metastases 3 (9%)</td>
<td>NR</td>
<td>Metastatic disease (two out of three patients died shortly after referral)</td>
</tr>
<tr>
<td>Starke et al. 2005</td>
<td>77</td>
<td>NR</td>
<td>Insulinoma</td>
<td>Metastases 10 (13)</td>
<td>2-year survival (metastatic only): 2.6 years</td>
<td>NR</td>
</tr>
<tr>
<td>Chen et al. 2002</td>
<td>74</td>
<td>NR</td>
<td>Insulinoma</td>
<td>Malignant insulinoma: 2 (3%)</td>
<td>All patients with benign insulinoma were cured. One patient with malignant insulinoma survived 18 years</td>
<td>NR</td>
</tr>
<tr>
<td>Feng et al. 2002</td>
<td>105</td>
<td>NR</td>
<td>Insulinoma</td>
<td>Malignant insulinoma: 4 (4%)</td>
<td>All patients with benign insulinoma were cured; three out of four patients with malignant insulinoma had relief of their symptoms and one died</td>
<td>NR</td>
</tr>
<tr>
<td>Boukhman et al. 1998</td>
<td>67</td>
<td>NR</td>
<td>Insulinoma</td>
<td>Malignant insulinoma: 10 (15%)</td>
<td>89% underwent a successful operation (no survival data reported)</td>
<td>NR</td>
</tr>
<tr>
<td>Kang et al. 2006</td>
<td>14</td>
<td>NR</td>
<td>Insulinoma 12 (86%) Gastrinoma 2 (14%)</td>
<td>Two malignant tumors (one insulinoma and one gastrinoma)</td>
<td>10 year survival: 81% (one patient died of unrelated causes)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Methylation of tumor suppressor genes has been implicated as an important factor in the etiology of various tumors. House et al. have shown that silencing of multiple tumor suppressor genes by promoter hypermethylation is frequent in PETs and may be associated with more advanced tumor stage and shorter survival (House et al. 2003b). The most frequently silenced genes were RASSF1A, p16/INK4A, O6-MGMT, RAR-β, and hMLH1 (House et al. 2003b). The association between RASSF1A and p16/INK4A methylation and more advanced stage was confirmed by other authors (Liu et al. 2005). Methylation of hMLH1 has also been shown to result in microsatellite instability in patients with PETs and may be associated with a favorable prognosis (House et al. 2003a). Telomerase activity has also been suggested as being useful in the diagnosis of PETs, and it has been suggested that the presence of telomerase activity may predict an unfavorable outcome (Lam et al. 2000, Tang et al. 2002, Vezzosi et al. 2006).

Studies using gene expression analysis can be powerful tools for prognostication of various tumors. Several investigators have used gene expression analysis in tumor tissue from patients with PET using microarray methods (Maitra et al. 2003, Bloomston et al. 2004, Durkin et al. 2004, Hansel et al. 2004, Capurso et al. 2006, Couvelard et al. 2006). Numerous genes have been found to be either over- or underexpressed, and these findings have been validated with immunohistochemical studies and PCR studies for several of the overexpressed genes. Genes found to be overexpressed in metastatic PETs when compared with non-metastatic PETs include Met proto-oncogene, IGF-binding protein 3 gene (IGFBP-3) as well as various genes involved in angiogenesis, signal transduction, cell cycle control, and ion transport (Hansel et al. 2004, Couvelard et al. 2006). Other investigators using a different set of overexpressed genes did not show a significant difference in gene expression between primary and metastatic lesions (Capurso et al. 2006).

Angiogenesis is important for tumor growth and formation of metastases, and several studies have evaluated the prognostic role of angiogenesis markers and mediators. Expression of Vascular endothelial growth factor (VEGF) has been associated with more aggressive tumor growth, the presence of metastases, and shorter progression-free survival in patients with low-grade neuroendocrine tumors when compared with tumors not expressing VEGF (Hansel et al. 2004).

---

Table 8 continued

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Number of patients</th>
<th>Median age (years)</th>
<th>Type of tumor (hormone produced)</th>
<th>Malignant PET (%)</th>
<th>number of patients with metastases</th>
<th>Survival Factors adversely affecting survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lundstrom et al. 1979 (Lundstrom et al. 1979)</td>
<td>12</td>
<td>1 (8)</td>
<td>Insulinoma</td>
<td>12</td>
<td>110</td>
<td>Insulinoma LN, lymph nodes; NR, not reported; OS, overall survival.</td>
</tr>
<tr>
<td>Zeng et al. 1999 (Zeng et al. 1998)</td>
<td>110</td>
<td>3 (13)</td>
<td>Insulinoma</td>
<td>12</td>
<td>110</td>
<td>Insulinoma LN, lymph nodes; NR, not reported; OS, overall survival.</td>
</tr>
<tr>
<td>Zeng et al. 1999 (Zeng et al. 1998)</td>
<td>110</td>
<td>3 (13)</td>
<td>Insulinoma</td>
<td>12</td>
<td>110</td>
<td>Insulinoma LN, lymph nodes; NR, not reported; OS, overall survival.</td>
</tr>
</tbody>
</table>

NR, not reported; LN, lymph nodes; OS, overall survival.

Microvessel density (MVD) in PETs has also received attention recently and decreased MVD may be an adverse prognostic factor according to some studies but not others (Marion-Audibert et al. 2003, La Rosa et al. 2003, Tan et al. 2004, Couvelard et al. 2005, 2006, Takahashi et al. 2007).

Conclusions

Pancreatic endocrine tumors (PETs) are uncommon tumors thought to originate from pluripotential cells in the exocrine pancreas. PETs account for only 1–3% of all neoplasms of the pancreas and their clinical behavior is much more indolent than that of adenocarcinoma of the pancreas. PETs are uncommon tumors with an annual incidence of <0.4 cases per 100 000. Asymptomatic PETs appear to be much more common according to large autopsy studies and frequently are undiagnosed in life. Functioning PETs are rare except for insulinomas and gastrinomas. The prognosis of PET is much better than that of pancreatic adenocarcinoma, even though patients are frequently diagnosed with metastatic disease. Multiple studies have shown that metastatic tumor and incomplete resection portend worse prognosis. Aggressive resection of the primary tumor as well as metastatic lesions may improve survival. Functional tumors may have a better prognosis in some studies, which may partly be explained by the much more benign nature and the favorable prognosis of the hormonally active insulinomas. Patients with functional tumors may also be diagnosed at an earlier stage, especially if they present with classical symptoms of hormone overproduction. Other prognostic factors include higher proliferative rate as manifested by increased number of mitoses as well as tumor necroses but those histological features are not universally reported by pathologists. Novel prognostic factors include increased expression of Ki-67, overexpression of angiogenesis markers, chromosomal aberrations, and overexpression of various genes as identified on microarray studies. Given the heterogeneous nature of PETs, it is unlikely that there will be a prognostic model applicable to all subtypes of these uncommon tumors.

Acknowledgements

We thank Ricardo V Lloyd MD, PhD for reviewing the manuscript. Research support: Mayo Clinic SPORE in Pancreatic Cancer (P50 CA 102701). The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Brandt ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A
et al. 2001 Guidelines for diagnosis and therapy of MEN
type 1 and type 2. Journal of Clinical Endocrinology 86
5658–5671.
Broughan KD, Johnston CF, O’Hare MM, Ardill JE, Shaw C,
Collins JS, Watson RG, Atkinson AB, Hadden DR,
Kennedy TL et al. 1986 Neuroendocrine tumors. A
Burgess JR, Greenaway TM, Parameswaran V, Challis DR,
David R & Shepherd JJ 1998a Enteropancreatic malign-
nancy associated with multiple endocrine neoplasia type
Burgess JR, Greenaway TM & Shepherd JJ 1998b
Expression of the MEN-1 gene in a large kindred with
multiple endocrine neoplasia type 1. Journal of Internal
Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F,
Milione M, Bhakta V, Campanini N, Swift SM, Bordi C,
Delle Fave G et al. 2006 Gene expression profiles of
progressive pancreatic endocrine tumours and their liver
metastases reveal potential novel markers and therapeutic
targets. Endocrine-Related Cancer 13 541–558.
Carriaga MT & Henson DE 1995 Liver, gallbladder,
Chen X, Cai WY, Yang WP & Li HW 2002 Pancreatic
insulinomas: diagnosis and surgical treatment of 74
patients. Hepatobiliary & Pancreatic Diseases International 1
458–461.
Chen YJ, Vortmeyer A, Zhuang Z, Huang S & Jensen RT
2003 Loss of heterozygosity of chromosome 1q in
gastrinomas: occurrence and prognostic significance.
Cancer Research 63 817–823.
Chen YJ, Vortmeyer A, Zhuang Z, Gibril F & Jensen RT
2004 X-chromosome loss of heterozygosity frequently
occurs in gastrinomas and is correlated with aggressive
Cheslyn-Curtis S, Sitaram V & Williamson RC 1993
Management of non-functioning neuroendocrine tumours
Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL,
Nava HR & Gibbs JF 2002 Predictive factors associated
with long-term survival in patients with neuroendocrine
tumors of the pancreas. Annals of Surgical Oncology 9
855–862.
Proliferative activity in pancreatic endocrine tumors:
association with function, metastases, and survival.
Endocrine Pathology 8 181–187.
Closet J, Delhaye M, Sperduto N, Rickaert F & Gelin M
1996 Nonfunctioning neuroendocrine tumors of the
pancreas: clinical presentation of 7 patients.
Hepatogastroenterology 43 1640–1644.
Corleto VD, Panzuto F, Falconi M, Cannizzaro R, Angeletti S,
Moretti A, Delle Fave G & Farinati F 2001 Digestive
neuroendocrine tumours: diagnosis and treatment in Italy.
A survey by the Oncology Study Section of the Italian
Society of Gastroenterology (SIGE). Digestive and Liver Disease 33
217–221.
Couvelard A, O’Toole D, Turley H, Leek R, Sauvanet A,
Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K
et al. 2005 Microvascular density and hypoxia-inducible
factor pathway in pancreatic endocrine tumours: negative
correlation of microvascular density and VEGF
expression with tumour progression. British Journal of
Couvelard A, Hu J, Steers G, O’Toole D, Sauvanet A, Belghiti J,
Identification of potential therapeutic targets by gene-
expression profiling in pancreatic endocrine tumors.
Gastroenterology 131 1597–1610.
Creutzfeldt W 1980 Endocrine tumors of the pancreas:
clinical, chemical and morphological findings.
Monographs in Pathology 21 208–230.
Cubilla AL & Hajdu SI 1975 Islet cell carcinoma of the
pancreas. Archives of Pathology 99 204–207.
Cullen RM & Ong CE 1987 Insulinoma in Auckland
Danforth DN Jr, Gorden P & Brennan MF 1984 Metastatic
insulin-secreting carcinoma of the pancreas: clinical
Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS,
Harmsen WS & Istrup DM 2000 Are patients with multiple
endocrine neoplasia type I prone to premature death?
Demeure MJ, Klonoff DC, Karam JH, Duh QY & Clark OH
1991 Insulinomas associated with multiple endocrine
neoplasia type I: the need for a different surgical approach.
Surgery 110 998–1005.
Deschamps L, Handra-Luca A, O’Toole D, Sauvanet A,
Ruszniewski P, Belghiti J, Bedossa P & Couvelard A
2006 CD10 expression in pancreatic endocrine tumors:
correlation with prognostic factors and survival. Human
Pathology 37 802–808.
Deshpande V, Fernandez-del Castillo C, Muzikansky A,
Deshpande A, Zakerberg L, Warshaw AL & Lauwers GY
2004 Cytokeratin 19 is a powerful predictor of survival
in pancreatic endocrine tumors. American Journal of
Surgical Pathology 28 1145–1153.
Doherty GM 2005 Multiple endocrine neoplasia type 1.
Journal of Surgical Oncology 89 143–150.
Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA
Jr & Norton JA 1998 Lethality of multiple endocrine
Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M &
Gimm O 2004 Surgery of resectable nonfunctioning
neuroendocrine pancreatic tumors. World Journal of
Surgery 28 1248–1260.
Durkin AJ, Bloomston M, Yeatman TJ, Gilbert-Barness E,
Cojita D, Rosemurgy AS & Zervos EE 2004 Differential
expression of the Tie-2 receptor and its ligands in human
pancreatic tumors. Journal of the American College of
Surgeons 199 724–731.


Formica V, Norman AR, Cunningham D, Wotherspoon A, Sirohi B, Oates J & Chong G 2006 The prognostic role of the WHO classification, urinary 5-hydroxyindoleacetic acid (u5HIAA) and liver function tests (LFTs) in metastatic neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract. *Journal of Clinical Oncology* **24** 4092.


